Combined BRAF(V600E) and MEK blockade for BRAF(V600E)-mutant gliomas

BRAF(V600E) is a common finding in glioma (about 10–60% depending on histopathologic subclassification). BRAF(V600E) monotherapy shows modest preclinical efficacy against BRAF(V600E) gliomas and also induces adverse secondary skin malignancies. Here, we examine the molecular mechanism of intrinsic r...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Neurooncol
Autors principals: Zhang, Jie, Yao, Tsun-Wen, Hashizume, Rintaro, Hariono, Sujatmi, Barkovich, Krister J., Fan, Qi-Wen, Prados, Michael, James, C. David, Weiss, William A., Nicolaides, Theodore
Format: Artigo
Idioma:Inglês
Publicat: 2016
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5560871/
https://ncbi.nlm.nih.gov/pubmed/27848137
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-016-2333-4
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars